Differences in allelic distribution at loci surrounding the human HLA-DRB1 and tumor necrosis factor (TNF) genes have been observed in association with systemic lupus erythematosus (SLE 24-6.11
Introduction
The chromosomal region encompassing the human leukocyte antigen (HLA) Class II to Class I genes has been implicated in susceptibility to systemic lupus erythematosus (SLE) and other autoimmune diseases, such as rheumatoid arthritis, insulin-dependent diabetes mellitus, atopic astma, multiple sclerosis, and Crohn's disease. [1] [2] [3] [4] [5] [6] [7] Alleles of the HLA-Class II gene, HLA-DRB1, are in linkage disequilibrium with genetic variations in the tumor necrosis factor (TNF) gene. 8, 9 Involvement of TNF in SLE was suggested by animal models, in which development of glomerulonephritis was delayed upon administration of recombinant TNF. 10 Disease activity in patients with SLE correlates with the levels of circulating TNF. 11 Recently, possession of the rare allele of a single nucleotide polymorphism located at −308 base pairs from the transcription initiation site in the promoter of TNF (TNF2, TNF−308A), was shown to be associated with susceptibility to SLE among AfricanAmericans. 12 Estimates of the allele frequency of the allele TNF−308A range from 17% to 28% in different Caucasian control populations. 8, [13] [14] [15] [16] [17] In our study among European Caucasians, the association between possession of TNF−308A and SLE was independent of the existing association between possession of the HLA-DRB1*0301 (HLA-DR3) allele and SLE, in spite of linkage disequilibrium between alleles of these loci. 18 This previously detected association between presence of a TNF−308A allele and susceptibility to SLE might be attributed to genetic variations in the region surrounding the TNF locus, apart from HLA-DR3. To investigate this possibility, we typed six microsatellite loci in a 1.8 million base-pair region encompassed by HLA-DRB1 and HLA-C in patients with SLE and controls.
Results

Demographic characteristics
The mean age of the patients was similar to that of the controls (39.6 ± 1.5 vs 38.6 ± 1.1 years, mean ± standard error). The patients were more often female than the controls (92% and 46% females, respectively), but this did not influence genotype distributions among patients and controls.
Allelic distribution of polymorphic markers
Homozygosity of polymorphic markers was largest for C1F3F2 with 39% in patients and 40% in controls and lowest in MIB, with 15% and 11%. Four percent of all subjects were homozygous for HLA-DR3 (7% in patients, 3% in controls) and 6% were homozygous for TNF−308A (14% in the patients, 3% in the controls).
Individual alleles were studied. The relative risk to develop disease, conferred by an extremely rare allele, may be larger than the relative risk conferred by a common allele, merely as a consequence of small numbers. To prevent the low background frequency of certain alleles from introducing spurious associations, the conclusions were restricted to the effects of either relatively common alleles (more than 20% frequency of persons possessing at least of these alleles), or alleles with a clear and distinctive impact on disease risk (unadjusted odds ratio or unadjusted odds ratio −1 of 2.5 or greater). Also, alleles that are bound to have such an impact merely on the basis of their low frequency, below 5%, are excluded. Frequencies of persons possessing these 22 selected alleles are depicted in Table 1 , with odds ratios representing the risk to develop SLE among persons with the allele compared with that among persons without the allele. Frequencies of the presence of 10 alleles were significantly different among the patients compared with controls (eight alleles present in increased frequencies, two alleles present in decreased frequency).
Stratified analysis
Confounder effects arise, for example due to linkage disequilibrium with HLA-DR3. To estimate the individual Odds ratio compares presence of at least one copy of the indicated allele to absence of that allele, among patients with SLE vs controls. *P value Ͻ 0.05. contribution of each risk factor and thus to adjust for the effect of linkage disequilibrium, a stratified analysis was undertaken. The risk to develop SLE in the presence of candidate alleles was studied in the presence and in the absence of HLA-DR3 separately. In Table 2 these odds ratios are depicted separately for the HLA-DR3-positive and DR3-negative strata. To summarize the effect of each allele in both strata combined, the weighed estimate of the stratum-specific odds ratios is given (Mantel-Haenszel odds ratio). This pooled odds ratio is an estimate of the effect of each allele on susceptibility to (or protection from) SLE, adjusted for its distribution over HLA-DR3-positive persons and HLA-DR3-negative persons.
By this analysis of effects across the separate strata, the consequences of linkage disequilibrium between studied alleles and HLA-DR3 became apparent. The odds ratios for presence of the alleles D6S1014*134 and MIB*350 became nonsignificant. This indicates that the effect of risk to develop SLE in the presence of these alleles is dependent on possession of HLA-DR3. For D6S273*139 and TNFa*99, the stratum-specific odds ratios appeared to indicate opposite effects among HLA-DR3-positive and HLA-DR3-negative persons (test indicating heterogeneity: P = 0.004 and P = 0.049, respectively). Therefore, the pooled odds ratio is inconclusive for D6S237*139 and TNFa*99. Possession of the alleles D6S1014*143, TNF−308A, C1F2F5*196 and C1F3F2*354 appeared to be statistically significantly associated with susceptibility to SLE, independent of possession of HLA-DR3. The effect was present and concordant in HLA-DR3-positives and HLA-DR3-negatives. Possession of C1F2F5*192 appeared protective, independent of possession of HLA-DR3. Lack of homogeneity across the strata. *Pooled odds ratio with P Ͻ 0.05.
Alleles of polymorphic markers in the vicinity of TNF, such as TNFa, might be in linkage disequilibrium to TNF−308 ( Figure 1 ). To adjust for this, risk to develop SLE dependent on various alleles was also analyzed after stratification on TNF−308A (Table 3) . Linkage disequilibrium between the TNFa*99 allele and TNF−308A became apparent when comparing the unadjusted odds ratio with the pooled odds ratio that adjusts for possession of Figure 1 Chromosomal location of polymorphic markers on the short arm of chromosome 6. Chromosomal location of HLA-DR, HLA-C, HLA-B, polymorphic microsatellite markers D6S1014, D6S273, TNFa, MIB, C1F2F5, and C1F3F2, and a single nucleotide polymorphism in the promoter of TNF. TNF G−308A. The relative positions of LTA, LTB and LST1 in the TNF gene cluster are indicated, as well as the relative positions of the genes encoding complement factor 4B, complement factor 4A, factor B, complement factor 2, heat-shock protein A1, and small nuclear ribonucleoprotein (C4B, C4A, Bf, C2, HSPA1 and snRNP) (not to scale).
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TNF−308A. Analysis in this particular group of patients and controls suggests that possession of TNFa*99 does not contribute significantly to susceptibility to SLE beyond possession of TNF−308A. There was heterogeneity across the strata in the comparison of D6S1014*134 and D6S273*139 (P Ͻ 0.05) and this prohibited further pooled analysis for these two alleles, stratified on possession of TNF−308A. Lack of homogeneity across strata. *Pooled odds ratio with P Ͻ 0.05.
The discordant effects of D6S273*139 among TNF−308A-positive and -negative persons resulted from an imbalanced distribution of D6S273*139 alleles over TNF−308A-positive and -negative strata. Forty-three out of 67 (64%) TNF−308A-carrying controls also had D6S273*139, and 21 out of 52 (40%) TNF−308A-carrying patients also had D6S273*139. These proportions were inverted among TNF−308-negative persons: two out of 186 (1%) TNF−308A-negative controls had D6S273*139, whereas six out of 39 (15%) TNF−308A-negative patients had D6S273*139.
Of all nine alleles tested, HLA-DR3, D6S1014*143, and C1F2F5 196 were statistically significantly associated with susceptibility to SLE, independent of the effect of TNF−308A. C1F2F5*192 was statistically significantly associated with protection from SLE, after adjustment for possession of TNF−308A (Table 3) .
Multivariate analysis
The preliminary analyses above suggested that some alleles are involved in susceptibility to SLE. These alleles were further investigated. To estimate the independent contribution of possession of these alleles, multivariate logistic regression was used.
In a first model, all 22 alleles from Table 1 
Dose-response and co-dominant effects
To investigate the possibility of a dose-response relation of the alleles suggested above, frequencies of heterozygotes and homozygtes with these alleles were compared with frequencies of persons without the allele. Odds ratios for these heterozygotes and homozygtes in patients and controls are depicted in Table 4 . Both heterozygous and homozygous possession of the alleles HLA-DR3, TNF-308A and C1F2F5*192 was statistically significantly associated with risk to develop SLE. This was not the case for D6S273*131. The odds ratio increased in a proportional manner for persons who possessed either zero, one or two TNF−308A alleles. No such proportional increase was observed for possession of the other alleles.
Discussion
Six microsatellite markers in the region surrounding the TNF locus, and HLA-DR3, did not explain a previously described association between possession of the A allele of a single nucleotide polymorphism in the promoter of TNF, TNF−308A, and susceptibility to SLE. Therefore we interpret this association as independent of the HLA-DR3 allele. The frequently reported association between possession of HLA-DR3 and risk to develop SLE was confirmed using a new control group. 18 The data also support an independent association of the allele C1F2F5*192 with protection from SLE. This allele might be in linkage disequilibrium with alleles from other polymorphic loci such as HLA-B.
These findings do not exclude the possibility that the TNF gene itself is causally related to the disease. Alternatively, alleles in linkage disequilibrium with alleles at the TNF gene or its promoter might be responsible for the association. For example, D6S273 alleles are in linkage disequilibrium with alleles at loci within the TNF gene cluster, in spite of the physical distance in-between of 150 000 base pairs. We found divergent effects at the D6S1014 and D6S273 loci. This might indicate the possibility of additional susceptibility loci located between HLA-DRB1 and TNF. This possibility is in agreement with the finding of altered allelic distribution at the D6S273 locus among patients with rheumatoid arthritis who did not possess the QKRAA/QRRAA epitope. 19 However, the divergence of the effects of the polymorphic markers under study does not directly support a role for such additional loci. The number of D6S273*139 alleles in the absence of TNF−308 A was very small both in our patients and our controls. Thus, small fluctuations in allelic frequencies between D6S273 and TNF−308 may lead to large shifts in the odds ratio of that particular stratum.
A possible association between alleles of marker loci within the TNF gene cluster and susceptibility to SLE has previously been suggested. [20] [21] [22] [23] Despite linkage disequilibrium between TNF−308A and TNFa*99, no additional or independent effect of TNFa*99 over HLA-DR3 was observed. This is in agreement with the previously reported linkage disequilibrium between TNFa*99 and HLA-DR3. 24 Stratified analysis suggested that possession of TNFa*99 could not predict susceptibility to SLE better than TNF−308A. This makes the interpretation less likely, that TNFa*99 or a gene in its immediate vicinity, such as the gene-encoding lymphotoxin-A (LTA), confers additional or independent susceptibility to SLE. TNFa is located 3500 base pairs telomeric from LTA, which is itself ca. 3000 base pairs telomeric from the TNF gene. 25 
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Centromeric from TNF, and located 275 kilo base pairs centromeric from D6S273, is one of the genes encoding the classical-pathway complement activator C4, C4A. 25 Complement component gene variations, particularly C4A gene deletions and silent alleles, have been implicated in susceptibility to SLE in various ethnic groups since the 1970s.
1,26-31 Indeed, a central European multicenter study of 300 patients with SLE and 453 of their first-degree relatives demonstrated that increased possession frequency of C4AQ0 among patients with SLE was dependent on possession of HLA-B8-DR3. 32 Strong linkage disequilibrium between these loci may not fully have been adjusted for in the present analysis, since C4A alleles were not typed in this population.
It has been suggested that inherited differences in TNF production are related to different alleles of the HLA-DRB1 locus. 24, 33 HLA-DR3 presence was suggested to be associated with high, and HLA-DR2 possession with low TNF production in mitogen-stimulated peripheral blood lymphocytes. 23, 34 Others could not confirm this. 16 Since the TNF promoter polymorphism at −308 base pairs from the transcription initiation site is present on the extended haplotype HLA-A1, B8, DR3, it has been attempted to attribute these associations between TNF production and HLA-genotypes to genetic variations in the TNF promoter. No association between TNF−308A or DR3 and endotoxin-induced production of TNF could however be demonstrated in peripheral blood samples of family members of patients with meningococcal disease, nor in broncho-alveolar lavage samples of patients with sarcoidosis. 17, 35 Others described increased production of TNF in the presence of both −308A and HLA-DR3. 13 This lack of functionality of the TNF−308 polymorphism might be explained by differences in stimulus or cell type used. 36 Since increased odds ratios both for heterozygous and homozygous presence of HLA-DR3, TNF−308A and C1F2F5*192 were observed, recessive effects of these alleles on susceptibility to SLE seem unlikely, whereas dominant and co-dominant effects might be possible. In the case of TNF−308A, the odds ratio for homozygous possession was higher than that for heterozygous possession. This is compatible with a gene-dose relation of TNF−308A, which strengthens the interpretation that this locus has causal relevance for the disease. For HLA-DR3 a gene-dose relation was not observed in the present sample.
The influence of confounding genetic determinants, due to linkage disequilibrium, was adjusted for by stratified analysis. The influence of a linked locus on the effects of alleles was analyzed by stratification according to possession or non-possession of the alleles at the linked locus. Since the microsatellite markers show a high degree of polymorphism, the chance of bearing an allele is affected by the chance of bearing any other allele at the locus. Among heterozygotes, the results of the stratified analysis may therefore have been influenced by possession of this second allele. Among homozygotes, there is no such influence. If, among the heterozygotes the second allele is responsible for the association, one might expect that the odds ratio (or odds ratio ) of heterozygous possession of the alleles HLA-DR3, TNF−308A, and C1F2F5*192 is substantially higher than the odds ratios of homozygous possession. For HLA-DR3 and C1F2F5*192, no difference was observed between the odds ratios of heterozygotes and homozygotes, whereas TNF−308A homozygotes had an increased risk to develop SLE compared with heterozygotes.
The allele C1F2F5*192 might point to a locus that is possibly involved in protection from SLE. Given the high degree of polymorphism of C1F2F5, the number of persons with the allele is inevitably small. The finding that a protective effect was nevertheless statistically significant, might indicate that the locus C1F2F5 points to a relevant genetic determinant for the disease. The protective effect of this allele might therefore be a reflection of a total effect of the other alleles at the locus. Since the locus C1F2F5 is located 75 kilo base pairs telomeric from HLA-B and 20 kilo base pairs centromeric from HLA-C, this effect might be due to linkage to HLA class I loci.
In conclusion, linkage disequilibrium to alleles from six polymorphic microsatellite markers in the region, and HLA-DR3, could not explain an independent association between TNF−308A and susceptibility to SLE.
Patients and methods
Study population
One hundred and seven consecutive Caucasian patients with SLE at the Rheumatology Department of Leiden University Medical Center (The Netherlands) were included. The recruitment of 99 of these patients has been described elsewhere. 18 All patients fulfilled the 1982 American College of Rheumatology (ACR) criteria for the classification of SLE as assessed by review of the medical records. For the present analyis, 278 Dutch Caucasian organ donors from the Department of Immunohaematology and Blood Transfusion of the Leiden University Medical Center served as a control population.
Amplification and determination of microsatellite markers DNA was isolated by phenol-chloroform extraction and ethanol precipitation of SDS-lysed and proteinase-K treated whole blood of the patients according to described methods. 37 Six polymorphic microsatellite markers, D6S1014, D6S273, TNFa, MIB, C1F2F5, and C1F3F2 were studied. Their chromosomal location is indicated in Figure 1 . The most centromeric of these microsatellites, D6S1014, is located in the vicinity of HLA-DR, whereas the other, more telomeric microsatellites, D6S273, MIB, TNFa, C1F2F5 and C1F3F2, encompass the HLA class III /TNF/lymphotoxin region and extend into HLA class I between HLA-C and HLA-B. Detailed information on these microsatellites have been published elsewhere. [38] [39] [40] Amplification was carried out by fluorescent-primer polymerase chain reaction (PCR) in a total reaction volume of 25 ml containing approximately 50 ng of genomic DNA, 12.5 pmol (D6S1014, MIB, C1F2F5 and C1F3F2) or 25 pmol (D6S73 and TNFa) of each primer, 200 mM of dNTPs (Pharmacia Biotech, Uppsala, Sweden), 5% (v/v) glycerol, and 2.5 units of Taq polymerase (Amplitaqâ, Perkin Elmer, Foster City, CA, USA). Amplification buffer contained 50 mM KCl, 1.5 mM MgCl2, 10 mM TrisHCl, at pH 8.4 (room temperature) and 0.06 mg/ml bovine serum albumin. Touchdown PCR was utilised to increase sensitivity of annealing during the first cycles (annealing temperature 58 to 68°C) using a Peltier Thermal Cycler (PTC-200, MJ Research, MA, USA).
For the patients' samples, PCR products were loaded onto a denaturing acrylamide sequencing gel (Reprogel High Resolution, Amersham Pharmacia Biotech) in Automated Laser Fluorescence-DNA sequencer (ALF-express II, Amersham Pharmacia Biotech). Electrophoresis (1500 V, 60 mA, 30 W at 55°C) and data collection were performed using ALF Manager software (Amersham Pharmacia Biotech). Data were analyzed using ALFWin Fragment Analyzer 1.01 software (Amersham Pharmacia Biotech). Allele assignment was performed by using CY-5 labeled internal size markers and running external allelic ladders over the size range of the involved microsatellite locus. Allelic ladders were composed of PCR products from Epstein-Barr virus-transformed lymphoblastoid cell lines, which had been sequenced previously. 41 Analysis of the control group was performed using a 96-lane ABI 377-DNA sequencer (Applied Biosystems, Foster City, CA, USA). Data were analyzed using Genescan 3.1 and Genotyper 2.0 software (Applied Biosystems). Accurate allele sizing was achieved using Genescan-ROX 400HD internal size marker (Applied Biosystems) and external allelic ladders were run as described above.
HLA-DRB1 typing HLA-DRB1 typing was performed by sequence specific oligonucleotide (SSO) typing on PCR amplified genomic DNA as previously described. 42 The presence of the HLA-DRB1*0301 allele will be referred to as HLA-DR3 possession.
Statistical analysis
Sixteen patients and 16 controls had incomplete typing data for all six microsatellites. Nine controls had incomplete data for the TNF−308 promoter gene polymorphism due to lack of DNA. This resulted in 91 patients and 253 controls for analysis.
Differences in allelic distribution of polymorphic markers between patients and controls were assessed by chisquare analysis. To estimate the relative risk of specific genetic risk factors, odds ratios with 95% confidence intervals were calculated according to Woolf. 43 In stratified analyses, Mantel-Haenszel's odds ratio was used to estimate the odds ratio pooled over strata. Discordance of stratum-specific effects, opposite effects across strata, was tested using Breslow and Days's homogeneity test. In logistic regression models, presence of alleles was simultaneously entered as categorical variables. The number of alleles in the model was stepwise reduced by backward regression, which removes each allele variable from the model equation as soon as its conditional likelihood ratio exceeds the threshold of 0.10. The remaining allele variables, all below the threshold, were considered allelepresence variables that independently predicted risk to develop SLE. Multivariate logistic regression analysis adjusts for multiple testing, as the hypotheses concerning individual alleles are all tested at the same time.
